Animal pharming, two decades on.
Since its inception 20 years ago, the animal pharming industry has promoted transgenic animals as a cost-effective method of biopharmaceutical production. However, it took until 2006 for the first therapeutic product to gain regulatory approval. This was an important milestone, but scepticism still abounds. Can pharming regain investor confidence, and will society accept transgenic livestock as a production method? There is some cause for optimism, biopharmaceuticals are a large, expanding market and animal pharming has already made considerable strides. A novel production platform has been established, groundbreaking technologies developed, a necessary regulatory framework put in place. Nevertheless, despite cost advantages, pharming has become a niche production method and its long term success may depend on products unique to transgenic animals.
Kind
Alexander
A
Livestock Biotechnology, Technische Universität München, Center of Life and Food Sciences Weihenstephan, Hochfeldweg, 1, Freising 85354, Germany.
Schnieke
Angelika
A
D000818:Animals; D000829:Animals, Domestic / Q000235:genetics*; D030801:Animals, Genetically Modified; D000911:Antibodies, Monoclonal / Q000097:blood* / Q000235:genetics*; D001702:Biopharmaceutics / Q000379:methods / Q000639:trends*; D006801:Humans
D000911:Antibodies, Monoclonal